World Health Organization urges scale-up of HIV self-testing

Roger Pebody
Published: 29 November 2016

HIV self-testing (sometimes called ‘home testing’) should be offered as an additional approach to HIV testing services, the World Health Organization (WHO) recommends in new guidelines issued today.

HIV self-testing “represents another step in line with efforts to increase patient autonomy, decentralize services and create demand for HIV testing among those unreached by existing services,” say WHO. They hope that it may increase testing rates in men, adolescents, men who have sex with men and other key populations.

Evidence to support the new guidance comes from five randomised controlled trials, including two Kenyan studies in which women distributed tests kits to their male partners, and three studies with men who have sex with men (MSM) in Australia, China and the United States. A number of observational studies were also consulted.

Key findings from the randomised studies were that, when compared with HIV testing in health facilities, self-testing increased the uptake of testing by male partners of pregnant women, increased the uptake of couples testing in this group, increased the uptake and frequency of testing in MSM, did not increase risky sexual behaviour or sexually transmitted infections (STI), did not lead to less STI testing, and did not increase intimate partner violence or other social harms.

WHO also conducted a systematic review and meta-analysis of test accuracy. It found that self-testers got as accurate results as trained health workers.

Self-tests using blood samples had a sensitivity (i.e. ability to give accurate results to people who have HIV) ranging from 96.2 to 100%. Blood-based tests had a specificity (i.e. ability to give accurate results to people who do not have HIV) ranging from 99.5 to 100%.

For tests using oral fluid samples, sensitivity ranged from 80 to 100% and specificity ranged from 95.1 to 100%. While this is a little less accurate, WHO do not recommend one form of test over another.

However, they do clearly state that any self-test used must be approved by the relevant regulatory authority. At present, only four tests have a CE mark for sale in Europe (BioSure, autotest VIH, INSTI and OraQuick) and only one test is approved by the US Food and Drug Administration (FDA) for sale in the United States (OraQuick). No test is yet pre-qualified by the World Health Organization (indicating that a test meets global standards for quality, safety and efficacy) but evaluation of a number of devices has begun.

The guidelines leave plenty of scope for countries and programmes to identify the best ways to distribute self-tests. Self-testing should aim to fill gaps in current coverage of HIV testing. It should reach people at high risk of HIV who do not use existing testing services often enough.

Distribution might be door-to-door, delivered by a person’s sexual partner, in healthcare facilities, integrated with outreach for other health programmes (such as male circumcision or TB screening), through workplace health programmes, in commercial pharmacies, online, or through vending machines.

Clear instructions for how to use a self-test and interpret the result must be provided. These may be provided through written, pictorial and video instructions and also remote support (e.g. a telephone hotline or online support). In some low-literacy settings it may be appropriate for self-testing to be ‘assisted’ by a healthcare or outreach worker who can demonstrate the process and be present while a person tests.

Clear messages are needed to describe what to do if the result is ‘reactive’ (potentially positive), WHO says. Users must understand that a reactive test result must be confirmed through further testing and should be given details of the services they can go to for this.

WHO acknowledge gaps in the evidence base on strategies to promote linkage to care after self-testing. Pro-active follow-up by peer or outreach workers may be appropriate, especially if the test was ‘assisted’. Studies suggest that allowing people to initiate HIV treatment at home (i.e. being visited by a counsellor at home and having medication delivered there) is effective. Phone hotlines, video counselling, appointment cards and vouchers (to cover transport costs) may also help linkage to care.

Clear messages are also needed so that people getting negative results understand that the result is not definitive, especially if the person’s last possible exposure to HIV was within the test’s window period. In the light of this, “HIV self-test results should not be used to serosort or to justify HIV risk behaviour such as condomless sex following a negative self-test result”. WHO says this advice is particularly relevant in communities where the rate of new infections is high, for example in most groups of gay men.

Information should be provided on disclosure, in particular to help couples cope with serodiscordant self-test results. Information on services to help with domestic abuse and intimate partner violence should be included. Self-testing is not recommended for couples in which abuse or violence is already a problem.

WHO says that many countries will need to adapt their national policies and regulations, so that HIV self-tests can be legally sold or distributed, non-healthcare workers can perform a test, and devices can be approved by regulatory authorities. Age of consent laws may need to be modified to allow adolescents to self-test for HIV. Laws and policies that address misuse (such as coercive testing and violence) may need to be adapted.

Reference

World Health Organization. Guidelines on HIV self-testing and partner notification: supplement to consolidated guidelines on HIV testing services, 2016. (Full text and supporting information freely available here).

WHO have produced a short video explaining self-testing, available on YouTube.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.